Cannabix Technol Stock Price, News & Analysis

Cannabix Technologies Inc. has announced a pilot program for its innovative Contactless Alcohol Breathalyzer (CAB) in collaboration with the Friedel Clinic in Montana. The CAB technology features wall-mounted and in-vehicle units, allowing employers to perform alcohol tests quickly and safely without contact. With high-volume drug testing, the Friedel Clinic plans to enhance workplace safety through this new technology. Current market trends show a push for alcohol detection systems in vehicles. However, the CAB is still in the preapproval phase, and no commercial sales are occurring yet.

Cannabix Technologies Inc. has partnered with the North Louisiana Criminalistics Laboratory (NLCL) to advance marijuana breathalyzer technology. This collaboration aims to enhance public safety by utilizing Cannabix's MS Breath Sampler for testing THC in breath samples. The NLCL will host this technology, enabling more efficient analysis of THC concentrations. Cannabix's approach simplifies the testing process, reducing time and costs significantly compared to traditional methods. CEO Rav Mlait expressed enthusiasm over this installation, marking a significant step in developing practical drug-screening devices for law enforcement and workplaces.

Cannabix Technologies is pioneering marijuana breathalyzer devices aimed at enhancing public safety. The company has partnered with the Warren County District Attorney’s office in Pennsylvania to pilot its breath collection units (BCU) for detecting THC in breath samples. The pilot program will see the deployment of two BCUs for potential usage over three months, targeting impaired driving detection. Cannabix's technology could revolutionize law enforcement protocols regarding cannabis consumption, aligning more closely with impairment timing and improving road safety.

Cannabix Technologies Inc. (CSE: BLO, OTC PINK: BLOZF) is advancing marijuana breathalyzer technology to enhance public safety. They are participating in a multi-analysis study in mid-October to test a new version of their FAIMS technology for detecting THC in breath. This follows prior testing events in June and July. The proprietary breath capture system minimizes sample preparation and significantly reduces analysis time, offering a promising alternative to traditional drug screening methods. Results indicate a consistent correlation between breath and blood THC levels, positioning Cannabix as a pioneer in cannabis impairment detection.

Cannabix Technologies continues to advance its marijuana breathalyzer technology, reporting progress in a comprehensive study conducted in the southern United States. The company’s FAIMS technology aims to detect THC in breath, correlating well with blood test results. Recent tests have demonstrated effective breath sample collection and analysis, eliminating traditional preparation steps and reducing costs. Cannabix seeks collaboration with law enforcement and other agencies to further develop these groundbreaking methods, while CEO Rav Mlait emphasizes their commitment to improving public safety.